These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 22123359)

  • 1. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
    Goldsmith SR; Gilbertson DT; Mackedanz SA; Swan SK
    J Card Fail; 2011 Dec; 17(12):982-9. PubMed ID: 22123359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
    Rademaker MT; Charles CJ; Nicholls MG; Richards AM
    Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
    Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.
    Yamazaki T; Izumi Y; Nakamura Y; Yamashita N; Fujiki H; Osada-Oka M; Shiota M; Hanatani A; Shimada K; Iwao H; Yoshiyama M
    Circ Heart Fail; 2012 Nov; 5(6):794-802. PubMed ID: 22984091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.
    Watanabe K; Dohi K; Sugimoto T; Yamada T; Sato Y; Ichikawa K; Sugiura E; Kumagai N; Nakamori S; Nakajima H; Hoshino K; Machida H; Okamoto S; Onishi K; Nakamura M; Nobori T; Ito M
    J Cardiol; 2012 Dec; 60(6):462-9. PubMed ID: 23068288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
    Chen HH; Redfield MM; Nordstrom LJ; Cataliotti A; Burnett JC
    Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
    Kurien S; Warfield KT; Wood CM; Miller WL
    Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive review of the loop diuretics: should furosemide be first line?
    Wargo KA; Banta WM
    Ann Pharmacother; 2009 Nov; 43(11):1836-47. PubMed ID: 19843838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators.
    Martin FL; Chen HH; Cataliotti A; Burnett JC
    Rev Cardiovasc Med; 2008; 9(1):39-45. PubMed ID: 18418308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased urinary aquaporin-2 excretion in response to furosemide in patients with chronic heart failure.
    Starklint J; Bech JN; Nyvad O; Jensen P; Pedersen EB
    Scand J Clin Lab Invest; 2006; 66(1):55-66. PubMed ID: 16464787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
    Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
    Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amlodipine and loop diuretics as the second anti-hypertensive medication for the treatment of hypertension with chronic kidney diseases.
    Takenaka T; Uchida K; Kojima E; Gen S; Nodaira Y; Hoshi H; Kato N; Takane H; Ohno Y; Suzuki H
    Clin Exp Hypertens; 2011; 33(4):210-5. PubMed ID: 21699446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure.
    Paterna S; Parrinello G; Cannizzaro S; Fasullo S; Torres D; Sarullo FM; Di Pasquale P
    Am J Cardiol; 2009 Jan; 103(1):93-102. PubMed ID: 19101237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure.
    Rogers HL; Marshall J; Bock J; Dowling TC; Feller E; Robinson S; Gottlieb SS
    J Card Fail; 2008 Feb; 14(1):1-5. PubMed ID: 18226766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
    Goldsmith SR; Elkayam U; Haught WH; Barve A; He W
    J Card Fail; 2008 Oct; 14(8):641-7. PubMed ID: 18926434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.